Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Estriol Vaginal Ring for Treating Vaginal Atrophy in Postmenopausal Women

InvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a new treatment for vaginal atrophy, a condition often experienced by postmenopausal women where the vaginal walls become thin, dry, and inflamed. The study will test a newly developed vaginal ring that releases estriol, a form of estrogen, in three different doses: 1 microgram per day, 10 micrograms per day, and 20 micrograms per day. There will also be a group using a placebo vaginal ring, which does not contain any active drug.

The purpose of the study is to evaluate how these different doses of estriol affect the vaginal tissue and pH levels over a period of 90 days. Participants will be randomly assigned to one of the treatment groups or the placebo group. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment until the study is completed. This helps ensure that the results are not biased.

Throughout the study, changes in the vaginal tissue and pH levels will be monitored to assess the effectiveness of the treatment. Additionally, a subgroup of participants will have their systemic exposure to estriol measured to understand how the body absorbs and processes the hormone. The trial aims to provide valuable information on the potential benefits of using estriol-releasing vaginal rings for treating vaginal atrophy in postmenopausal women.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be assigned to one of the treatment groups. This assignment is random, and neither you nor the study team will know which group you are in. This is called a double-blind study.

  2. Step 2

    Treatment administration

    You will receive a vaginal ring to use. This ring may contain one of three doses of the active substance estriol or it may be a placebo, which does not contain any active drug.

    The doses of estriol in the rings are either 1 microgram per day, 10 micrograms per day, or 20 micrograms per day. The ring is designed for vaginal use and will be worn continuously.

  3. Step 3

    Duration of treatment

    The treatment will last for 90 days. During this time, you will continue to use the vaginal ring as instructed.

  4. Step 4

    Monitoring and assessments

    Throughout the study, there will be regular assessments to monitor changes in your condition. This includes evaluating the cytologic pattern of your vaginal lining and measuring your vaginal pH.

    A subgroup of participants will also have their systemic exposure to estriol measured. This involves checking how much of the drug is present in your body over time.

  5. Step 5

    End of treatment evaluation

    At the end of the 90-day treatment period, there will be a final evaluation to assess the changes from the start of the study. This will include checking the vaginal maturation value, the percentage of vaginal superficial cells, and the percentage of vaginal parabasal cells.

    The study will also determine the proportion of participants who have achieved a vaginal pH of 5 or lower.

Who can join the trial?

7 criteria

  • Age: You must be **45 years or older**.
  • Postmenopausal state: You should have had your last natural menstrual period at least **1 year ago** and have a blood test showing a hormone level called **FSH** of **40 IU/l** or higher.
  • Vaginal Maturation Value: This is a test result that should be **50% or less** at the start of the study.
  • Vaginal pH: Your vaginal pH level should be **greater than 5.0** at the start of the study.
  • Symptoms of Vaginal Atrophy: You should have at least one symptom such as **dryness, pain or burning sensation, itching, discharge, painful urination, urinary incontinence, or pain during intercourse**. These symptoms should be rated at a score of **65 or higher** on a scale used to measure them.
  • Smoking status: You should be a **non-smoker** or have quit smoking for at least **3 months**.
  • Consent: You must provide **written informed consent** after being informed about the benefits and potential risks of the clinical trial, as well as details of the insurance covering participants in this trial.

Who cannot join the trial?

4 criteria

  • Patients who are not experiencing vaginal atrophy cannot participate. Vaginal atrophy is a condition where the walls of the vagina become thin and dry.
  • Only female patients can participate in this study.
  • Patients who are male cannot participate.
  • Patients who are considered part of a vulnerable population cannot participate. This means groups of people who might need special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Estriol Vaginal Ring is a newly developed treatment designed to help with vaginal atrophy, a condition that can occur in postmenopausal women. This condition often leads to symptoms like dryness, irritation, and discomfort in the vaginal area. The vaginal ring releases estriol, a form of estrogen, directly into the vaginal tissue. This helps to improve the health of the vaginal lining by making it thicker and more elastic, which can reduce symptoms and improve comfort. The trial is investigating how effective this treatment is by looking at changes in the vaginal cells and pH levels after 90 days of use. Additionally, the study is examining how much estriol enters the bloodstream in a subgroup of patients to ensure the treatment is safe and effective.

What is already known about the treatment

Estriol Vaginal Ring – This medication is administered as a vaginal ring, which is a flexible device inserted into the vagina. It is currently being studied in clinical trials for its effectiveness in treating vaginal atrophy, a condition common in postmenopausal women where the vaginal walls become thin and dry. The main therapeutic indication is to alleviate symptoms associated with vaginal atrophy. At the molecular level, estriol, a form of estrogen, works by binding to estrogen receptors in the vaginal tissue, promoting the growth and maintenance of healthy vaginal cells. It is classified pharmacologically as an estrogen hormone therapy.

Investigated diseases

Vaginal atrophy – Vaginal atrophy is a condition characterized by the thinning, drying, and inflammation of the vaginal walls. It typically occurs when the body produces less estrogen, such as during menopause. The condition can lead to symptoms like vaginal dryness, itching, and discomfort during intercourse. As the condition progresses, the vaginal tissue becomes more fragile and less elastic. This can result in increased susceptibility to irritation and infection. Changes in the vaginal environment, such as increased pH levels, are also common as the condition develops.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-514302-31-00Protocol code1452est24ctEstimated enrolment112 patientsSponsorSocraTec R&D Concepts in Drug Research and Development GmbH

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).